Monitor Tevogen's progress toward the $1.0 billion revenue milestone and any future 13D amendments for changes in Desai's stake or intentions. The high vesting bar suggests this is a long-term incentive, not a near-term catalyst.
Price Chart
Executive Summary
Kirti Desai filed an amended Schedule 13D disclosing a grant of 750,000 restricted shares on September 14, 2026, increasing his beneficial ownership to 992,983 shares (6.3% of the outstanding common stock). The restricted shares vest only upon Tevogen achieving $1.0 billion in aggregate revenue by September 30, 2031, an extremely high bar for a pre-revenue biotech. This is a routine compensatory grant, not an activist escalation, and the filing does not change Desai's stated purpose or demands.
Key Financial Metrics
Key Facts
- Kirti Desai now beneficially owns 992,983 shares of Tevogen common stock, representing 6.3% of the 15,736,540 shares outstanding as of September 14, 2026.
- Desai received a grant of 750,000 restricted shares on September 14, 2026, under the Tevogen Inc. 2024 Omnibus Incentive Plan.
- The restricted shares vest only upon written Board certification that Tevogen achieved $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031.
- The shares are subject to forfeiture if the revenue threshold is not met, upon termination of service, misconduct, or transfer prior to vesting.
- No other transactions in common stock were reported in the 60 days prior to this filing.
Financial Impact
No immediate financial impact. The restricted stock grant is compensatory with a performance condition tied to $1.0 billion in aggregate revenue by 2031.
Risk Factors
- The $1.0 billion revenue target is extremely ambitious for a pre-revenue biotech; the restricted shares may never vest.
- No change in activist demands or escalation; this is a routine compensatory filing.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001123292-26-001316 |
| Document: 0001123292-26-001316-index.html | 0001123292-26-001316 |
| Document: 0001123292-26-001316.txt | 0001123292-26-001316 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $6.72 | awaiting T+60 | — | $6.25 (−6.99%) |
Sep 16, 2026 5w ago | SC 13D/A | $7.71 | awaiting T+60 | — | $6.25 (−18.94%) |
Sep 16, 2026 5w ago | SC 13D/A | $7.71 | awaiting T+60 | — | $6.25 (−18.94%) |
Sep 16, 2026 5w ago | 8-K | $7.71 | awaiting T+60 | — | $6.25 (−18.94%) |
Jun 26, 2026 17w ago | EFFECT | $7.00 $7.43 | ▼ −6.14% | ▼ −1.66% | $6.25 (+10.71%) |
Jun 12, 2026 19w ago | S-3 | $10.02 $7.34 | ▲ +26.75% | ▲ +27.75% | $6.25 (+37.62%) |
Jun 9, 2026 19w ago | Press Release | $10.75 $7.17 | ▼ −33.30% | ▼ −37.12% | $6.25 (−41.86%) |
May 28, 2026 21w ago | Press Release | $8.04 $6.75 | ▼ −16.04% | ▼ −17.78% | $6.25 (−22.26%) |
May 21, 2026 22w ago | Press Release | $11.57 $6.58 | ▼ −43.10% | ▼ −47.40% | $6.25 (−45.96%) |
Mar 25, 2026 30w ago | Press Release | $5.18 $9.79 | ▲ +88.90% | ▲ +75.44% | $6.25 (+20.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers